Felix Geller, MD
Psychiatry · Toms River, NJNPI 1902073216
Payments from drug & device makers
Across 547 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Axsome Therapeutics, Inc.$937
- plus $3K from 24 others
What the payments were for
- Food & beverage$11,36797%
- Education$3053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,643 |
| Alkermes, Inc. | 65 | $1,512 |
| Teva Pharmaceuticals USA, Inc. | 69 | $1,497 |
| AbbVie(2 entities) | 56 | $1,483 |
| Otsuka America Pharmaceutical, Inc. | 76 | $1,384 |
| Axsome Therapeutics, Inc. | 50 | $937 |
| Johnson & Johnson | 22 | $476 |
| Braeburn Inc. | 12 | $407 |
| Neurocrine Biosciences, Inc. | 15 | $396 |
| Indivior Inc. | 17 | $269 |
| Supernus Pharmaceuticals, Inc. | 13 | $244 |
| Vanda Pharmaceuticals Inc. | 14 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $179 |
| Eisai Inc. | 5 | $178 |
| Tris Pharma Inc | 11 | $173 |
| Corium, LLC | 10 | $152 |
| E.r. Squibb & Sons, L.L.C. | 5 | $101 |
| Noven Therapeutics, LLC | 5 | $76 |
| Neuronetics, Inc. | 1 | $68 |
| Ironshore Pharmaceuticals Inc. | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 7 | $54 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Sage Therapeutics, LLC | 2 | $31 |
| Almatica Pharma LLC | 2 | $28 |
| Harmony Biosciences LLC | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Life Molecular Imaging Ltd | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,671 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 240 | $348,722 |
| Austedo XrDeutetrabenazine | 33 | $215,875 |
| Invega SustennaPaliperidone Palmitate | 51 | $187,494 |
| IngrezzaValbenazine Tosylate | 16 | $137,789 |
| RexultiBrexpiprazole | 83 | $133,529 |
| CaplytaLumateperone Tosylate | 58 | $124,458 |
| Abilify MaintenaAripiprazole | 26 | $85,536 |
| AustedoDeutetrabenazine | 15 | $82,759 |
| AuvelityDextromethorphan Hbr/Bupropion | 106 | $78,084 |
| VivitrolNaltrexone Microspheres | 26 | $58,300 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $52,251 |
| TrintellixVortioxetine Hydrobromide | 50 | $39,610 |
| Aripiprazole | 358 | $29,524 |
| FanaptIloperidone | 12 | $28,573 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 100 | $13,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,483 | $348,722240 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,497 | $298,63448 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,384 | $219,065109 claims |
| Johnson & JohnsonInvega Sustenna | $476 | $187,49451 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $396 | $137,78916 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,643 | $124,45858 claims |
| Alkermes, Inc.Vivitrol, Lybalvi | $1,512 | $110,55258 claims |
| Axsome Therapeutics, Inc.Auvelity, Sunosi | $937 | $88,155117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $179 | $39,61050 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $207 | $28,57312 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $35 | $13,441100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Toms River
- Matthew PiteraToms River$153K
- Leon RosenbergCherry Hill$6.4M
- Steven GlassClementon$3.9M
- Judith JosephPaterson$3.8M
- Jeffrey ApterPrinceton$1.7M
- Roberta BallCherry Hill$741K
- Marc CantillonLivingston$524K
- Sanjay VarmaPrinceton$479K
- Manuel SanchezNewark$474K
- Robert BransfieldRed Bank$415K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.